Skip to main content
Terug
Watch Compare

China SXT Pharmaceuticals, Inc.

Datakwaliteit: 83%
SXTC
NASDAQ Manufacturing Chemicals
€ 2,32
▲ € 0,25 (12,08%)
Marktkapitalisatie: 1,77 M
Prijs
€ 2,07
Marktkapitalisatie
1,77 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Debt/Equity of 0,12 — conservative balance sheet
Negative free cash flow of -2,35 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-32,85%
Boven sectorgemiddelde (-53,58%)
ROIC-19,41%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
0,12
Onder sectorgemiddelde (0,30)
Current Ratio1,40
Interest Coverage-25,23

Waardering

PE (TTM)
-0,53
Boven sectorgemiddelde (-1,48)
P/B Ratio0,12
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1366 peers)
Metriek Aandeel Sector Mediaan
P/E -0,5 -1,5
P/B 0,1 1,6
ROE % -32,9 -53,6
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E 0,1 0,3

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Geen toekomstige schattingen beschikbaar

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -3,30 M
ROE -32,85% ROA -14,49%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -2,35 M
ROIC -19,41% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,12 Current Ratio 1,40
Interest Coverage -25,23 Asset Turnover N/A
Working Capital 6,32 M Tangible Book Value 15,02 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,53 Forward P/E N/A
P/B Ratio 0,12 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -132,75%
Market Cap 1,77 M Enterprise Value -14,97 M
Per Share
EPS (Diluted TTM) -2,32 Revenue / Share N/A
FCF / Share -2,75 OCF / Share -2,75
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 70,99%
SBC-Adj. FCF N/A Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — 1,93 M 1,97 M 2,60 M 4,78 M
Net Income -3,30 M -3,10 M -5,93 M -5,74 M -2,75 M
EPS (Diluted) -2,32 -3,57 -0,89 — —
Gross Profit 367.427,0 553.971,0 426.271,0 1,25 M 2,84 M
Operating Income -2,68 M -2,52 M -5,61 M -5,19 M -2,20 M
EBITDA — — — — —
R&D Expenses — 184.194,0 — — —
SG&A Expenses — — — — —
D&A 82.297,0 203.247,0 250.162,0 320.007,0 345.414,0
Interest Expense 106.238,0 544.279,0 476.776,0 36.695,0 1,62 M
Income Tax — 328.146,0 328.146,0 328.146,0 -192.683,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 21,66 M 23,13 M 29,55 M 33,55 M 34,55 M
Total Liabilities 6,22 M 9,20 M 14,86 M 17,12 M 18,59 M
Shareholders' Equity 15,44 M 13,93 M 14,69 M 16,42 M 15,96 M
Total Debt 1,51 M 1,12 M 285.315,0 17.696,0 43.414,0
Cash & Equivalents 18,10 M 12,07 M — — 13,36 M
Current Assets 21,30 M 14,23 M 19,52 M 22,45 M 23,23 M
Current Liabilities 6,01 M 8,90 M 14,50 M 17,12 M 18,58 M